Ionis Pharmaceuticals (IONS) News Today $32.78 +0.10 (+0.31%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A.Assenagon Asset Management S.A. grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 967.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,917 shares of the company's stJanuary 21 at 3:13 AM | marketbeat.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 7,154 Shares of StockJanuary 18, 2025 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 SharesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 7,154 shares of the company's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the sale, the executive vice president now owns 45,670 shares of the company's stock, valued at $1,499,802.80. This trade represents a 13.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.January 17, 2025 | marketbeat.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Sells 8,870 Shares of StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CFO Elizabeth L. Hougen sold 8,870 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $32.81, for a total value of $291,024.70. Following the completion of the transaction, the chief financial officer now owns 107,885 shares of the company's stock, valued at approximately $3,539,706.85. The trade was a 7.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 17, 2025 | marketbeat.comBrett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 33,445 shares of the business's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the transaction, the chief executive officer now owns 207,396 shares in the company, valued at $6,767,331.48. The trade was a 13.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.January 17, 2025 | marketbeat.comIonis Pharmaceuticals EVP Brian Birchler sells $176,580 in stockJanuary 17, 2025 | msn.comIonis Pharmaceuticals CEO Brett Monia sells $1.09 million in stockJanuary 17, 2025 | msn.comIonis Pharmaceuticals: Strong Pipeline and Market Potential Drive ‘Buy’ RatingJanuary 17, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Given Outperform Rating at Royal Bank of CanadaJanuary 17, 2025 | americanbankingnews.comIonis Pharmaceuticals, Inc. (IONS) Stock ForecastsJanuary 16, 2025 | ca.finance.yahoo.comIonis Pharmaceuticals (IONS) Gets a Hold from BernsteinJanuary 16, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year Low - Here's WhyIonis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month Low - Should You Sell?January 16, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)January 16, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday.January 15, 2025 | marketbeat.comAmyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034January 15, 2025 | globenewswire.comIonis Pharmaceuticals: Promising Pipeline and Strategic Shifts Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comIonis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comIonis unveils pipeline plan for 2025, expects 4 independent product launchesJanuary 13, 2025 | markets.businessinsider.comIonis Pharmaceuticals: Hold Rating Amid Uncertainty in Future Financial PerformanceJanuary 13, 2025 | markets.businessinsider.comIonis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentumJanuary 13, 2025 | prnewswire.comInternational Assets Investment Management LLC Has $285,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)International Assets Investment Management LLC lowered its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 97.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,207 sharesJanuary 13, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year Low - Here's What HappenedIonis Pharmaceuticals (NASDAQ:IONS) Reaches New 1-Year Low - Here's What HappenedJanuary 10, 2025 | marketbeat.comIonis to present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | prnewswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nineteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hJanuary 8, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Anteris Technologies Global Corp. (AVR)January 7, 2025 | markets.businessinsider.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Purchases $181,100.00 in StockDecember 27, 2024 | insidertrades.comInsider Buying: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Purchases 5,000 Shares of StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Michael R. Hayden bought 5,000 shares of the stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $36.22 per share, with a total value of $181,100.00. Following the completion of the acquisition, the director now directly owns 35,219 shares of the company's stock, valued at approximately $1,275,632.18. The trade was a 16.55 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.December 26, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)December 23, 2024 | markets.businessinsider.comIonis Pharmaceuticals: Promising Growth From Tryngolza ApprovalDecember 23, 2024 | seekingalpha.comFY2028 Earnings Estimate for IONS Issued By William BlairIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at William Blair reduced their FY2028 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Friday, December 20th. William Blair analyst M. Minter now anticipatesDecember 23, 2024 | marketbeat.comIonis stock rises following FDA approval of TRYNGOLZADecember 21, 2024 | ca.investing.comIonis gets FDA approval for TryngolzaDecember 21, 2024 | msn.comThe Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 ExpertsDecember 21, 2024 | benzinga.comIonis Pharmaceuticals (NASDAQ:IONS) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday.December 20, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Receives "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday.December 20, 2024 | marketbeat.comTRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietDecember 19, 2024 | prnewswire.comUS FDA approves Ionis Pharma's genetic disorder drugDecember 19, 2024 | reuters.comGeode Capital Management LLC Has $106.92 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Geode Capital Management LLC increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 7.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,668,358 shares of the company's stock after purchasing an additional 183,814 sharDecember 19, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 5.4% in NovemberIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 10,450,000 shares, a decrease of 5.4% from the November 15th total of 11,050,000 shares. Currently, 7.2% of the shares of the stock are short sold. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is presently 6.1 days.December 17, 2024 | marketbeat.comY Intercept Hong Kong Ltd Takes $807,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Y Intercept Hong Kong Ltd acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,141 shares of the company's stoDecember 14, 2024 | marketbeat.comStifel Financial Corp Sells 33,635 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Stifel Financial Corp lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 182,505 shares of the company's stock after selling 33,635 shares during theDecember 14, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nineteen analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recoDecember 14, 2024 | marketbeat.comXTX Topco Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)XTX Topco Ltd bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 16,805 shares of the company's stock, valued at approximately $673,000. SevDecember 13, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Gets a Buy from OppenheimerDecember 10, 2024 | markets.businessinsider.comGroupama Asset Managment Raises Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Groupama Asset Managment lifted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 916,060 shares of the comDecember 10, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?December 7, 2024 | uk.finance.yahoo.comIonis Pharmaceuticals management to meet with OppenheimerDecember 6, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Purchases 77,909 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Jacobs Levy Equity Management Inc. raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 650,779 shares of the comDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Erste Asset Management GmbH acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 51,300 shares of the company's stock, valued at approximaDecember 4, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Buys 34,097 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)The Manufacturers Life Insurance Company raised its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 12.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 308,947 shares of the company's stock after acquiring anDecember 3, 2024 | marketbeat.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.200.63▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼167▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UTHR News Today NBIX News Today INCY News Today BMRN News Today EXEL News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today ALKS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
